Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention
Open Access
- 1 June 2016
- journal article
- research article
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 32 (6) , 747-753
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial FibrillationCanadian Journal of Cardiology, 2014
- Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registryBlood, 2014
- The Clinical Profile and Pathophysiology of Atrial FibrillationCirculation Research, 2014
- Efficacy and Safety of Dabigatran Etexilate and Warfarin in “Real-World” Patients With Atrial FibrillationJACC, 2013
- 2012 focused update of the ESC Guidelines for the management of atrial fibrillationEP Europace, 2012
- Oral Anticoagulant TherapyChest, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2009
- Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam studyEuropean Heart Journal, 2006